Titan Pharmaceuticals, Inc - Recent Material Event
| Item 8.01. | Other Events. |
On February 9, 2012, Titan Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the positive results of an open-label, six-month safety re-treatment study of patients with opioid dependence who previously completed a full six months of treatment in the Company’s confirmatory Phase 3 clinical trial of the investigational drug Probuphine™.
The press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits |
(d) Exhibits
| 99.1 | Press Release dated February 9, 2012 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| TITAN PHARMACEUTICALS, INC. | ||
| By: | /s/ Sunil Bhonsle | |
| Name: | Sunil Bhonsle | |
| Title: | President | |
Dated: February 10, 2012
Exhibit Index
| Exhibit No. |
Description | |
| 99.1 | Press Release dated February 9, 2012 | |